摘要
目的 探讨p16和Smad4在人肺腺癌组织中的表达缺失及其与临床病理特征和预后的关系.方法 免疫组织化学法检测p16、Smad4蛋白在120例肺腺癌组织中的表达缺失,探讨p16和Smad4缺失表达与肺腺癌患者临床病理因素及预后的关系.结果 p16和Smad4在肺腺癌组织中的表达缺失率分别为45.0％和62.5％.p16的表达缺失与肿瘤的淋巴结转移（P＜0.01）和临床病理分期明显相关（P＜0.01）,Smad4的表达缺失与肿瘤大小（P＜0.05）,淋巴结转移（P＜0.05）以及肿瘤分化程度（P＜0.05）明显相关.p16和Smad4的表达缺失率与患者总生存期呈负相关（P＜0.01）,p16和Smad4表达共缺失者的总生存期最短（P＜0.01）.p16的表达缺失率与Smad4的表达缺失率呈正相关（r =0.182,P＜0.05）.结论 p16和Smad4在肺腺癌中表达缺失与肺腺癌的恶性生物学行为和不良预后有关.
Objective To investigate the loss of p16 and Smad4 expression in human lung adenocarcinoma and their relationship with the clinicopathological characteristics and prognosis.Methods The protein expression of p16 and Smad4 in 120 cases of lung adenocarcinoma tissues was detected.The relationship between the expression of these proteins and clinicopathological features was analyzed,and the application of p16 and Smad4 in disease prognosis was evaluated.Results The loss frequency of p16 and Smad4 in lung adenocarcinoma tissues was 45.0% and 62.5%,respectively.Loss of p16 expression was associated with lymph node metastasis （P 〈 0.01） and clinicopathological stage （P 〈 0.01）.Loss of Smad4 expression was associated with tumor size （P 〈 0.05）,lymph node metastasis （P 〈 0.05）,and tumor differentiation （P 〈 0.05）.Loss of p16 and Smad4 expression was negatively correlated with overall survival,and the overall survival time in patients with two genetic loss was shortest （P 〈 0.01）.The Spearman correlation analysis showed that the expression of p16 had a positive correlation with the expression of Smad4 （r =0.182,P 〈 0.05）.Conclusion The loss of p1 6 and Smad4 expression in lung adenocarcinoma was associated with malignant biological behaviors and poor prognosis.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2014年第10期2310-2313,共4页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金资助项目（81372321）
汀苏省科技厅重大专项基金资助项目（BL2012030）
江苏省恶性肿瘤分子生物学及转化医学重点实验室专项基金资助项目（BM2013007）
